News Sentiment

RXST sentiment intelligence

Rxsight Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 64 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Medical Devices Read-through group
Latest close 5.55 Week of 17 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

75/100 classification confidence.

Company focus 53

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend inactive

+12.1% over one week, +17.3% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

BlackRock Portfolio Management (RXST) discloses 7.2% beneficial stake in RxSight

Market Reaction

Price moving ahead of tone

61/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 75/100 classification
One-week reaction 12.1% Price confirming higher
Trend fit Trend inactive 17.3% over four weeks
Fair value -80.1% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 17
Neutral 39
Negative 8

Relevance

Why the article matched

Direct first
Direct company coverage 53
Industry context 11
Sector context 0

Sources

Coverage mix

Publishers
Market source 19
Stock Titan 8
GlobeNewswire 6
Investing.com 4
Moomoo 2
Simply Wall Street 2
VisionMonday.com 2
MT Newswires 2

Event Lens

What the news is about

Classified themes
Market update 26
Earnings 18
Deals and strategy 6
Guidance 5
Analyst action 4
Regulatory and legal 4
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 64
StreetInsider Direct company coverage

RxSight Inc. (RXST) PT Lowered to $6.50 at BofA Securities

BofA Securities analyst Craig Bijou has lowered the price target for RxSight Inc. (NASDAQ: RXST) to $6.50 from $8.00. The analyst maintained their rating on the stock. The article is premium content, requiring a subscription to read further details.

Tone
Negative 30/100
Event
Analyst action
Published
07 Jul 2026 12:24
Source
StreetInsider
Market source Direct company coverage

Alcon spends up to $200m to co-develop customisable cataract lenses with RxSight

Alcon and RxSight have partnered to co-develop presbyopia-correcting intraocular lenses (PCIOLs) for cataract patients, with Alcon investing up to $200 million. This collaboration aims to combine RxSight's light-adjustable technology with Alcon's optical designs to create customi

Tone
Positive 73/100
Event
Market update
Published
07 Jul 2026 11:11
Source
Market source
Market source Direct company coverage

Alcon and RxSight Announce Collaboration to Develop Adjustable PCIOLs

Alcon and RxSight have announced a non-exclusive collaboration to develop adjustable presbyopia-correcting intraocular lenses (PCIOLs). This partnership aims to combine RxSight's light-adjustable technology with Alcon's PCIOL optical designs to allow surgeons to fine-tune visual

Tone
Positive 75/100
Event
Deals and strategy
Published
07 Jul 2026 08:11
Source
Market source